Sulzer Inter Op
This article was originally published in The Gray Sheet
Executive Summary
Financial impact of voluntary December 5 recall of the acetabular shell hip implant will be larger than initially anticipated as revision surgeries exceed 1,700 to date, the firm reports May 21. Insurance will be insufficient to meet the firm's commitment to "fair" reimbursement of related expenses, contrary to earlier projections, Sulzer says. The firm notes weekly surgeries are declining, however. The recall stems from aseptic loosening due to residue left on the shell's surface from the machining process (1"The Gray Sheet" Jan. 22, 2001, p. 14)
You may also be interested in...
Sulzer Inter-Op Hip Shell Loosening Detected In 129 Patients Following Recall
The financial impact of Sulzer Orthopedics' Inter-Op acetabular shell hip implant recall Dec. 5 "will be more than offset" by a $32 mil. one-time payment from a separate litigation settlement to its Sulzer Spine-Tech subsidiary, the firm predicts.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.